Lurasidone – Kodiac biolabs

Plain-language summaryIntrigue 67 / 100

Lurasidone (Latuda) is a Japanese atypical antipsychotic from Sumitomo Dainippon, approved by the FDA in 2010. It blocks dopamine D2, serotonin 5-HT2A, and 5-HT7 receptors in roughly balanced fashion, with very little activity at histamine or muscarinic receptors. That receptor profile gives it the lowest metabolic burden of the atypical antipsychotic class: minimal weight gain, minimal lipid or glucose disturbance, and minimal sedation. The 5-HT7 antagonism appears to contribute distinct procognitive and antidepressant effects, which is why it is approved for both schizophrenia and bipolar depression. The catch is that absorption is highly food-dependent: it must be taken with at least 350 calories or it does not work properly. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

59/100

Reference 5-HT7 antagonist among approved antipsychotics with a clean metabolic and sedation profile

Look, lurasidone doesn’t show up in our library because it needs introduction. It’s Latuda. It’s been an approved atypical antipsychotic since 2010, used by millions of patients, and the core D2/5-HT2A story is as well-understood as anything in that class gets. The reason it earns a place here isn’t the receptor profile everyone already knows — it’s the 5-HT7 component, and specifically what that means for investigators trying to do clean receptor-level work in bipolar depression or cognitive-outcome models.

The 5-HT7 receptor is underappreciated. It’s a Gs-coupled receptor widely expressed in the SCN, thalamus, and limbic circuitry, implicated in circadian entrainment, mood regulation, and cognitive processing in ways the traditional D2 and 5-HT2A blockade story doesn’t fully explain. Lurasidone’s Ki at 5-HT7 sits around 0.5 nM — making it the most potent 5-HT7 antagonist among all approved antipsychotics in clinical use. That’s not a small thing. When you want to study 5-HT7 contribution to antidepressant effect in a system that also needs regulatory-grade pharmacokinetics and an established safety profile, lurasidone is the reference tool.

What we like is the selectivity shape. Minimal H1 activity means the sedation confound that wrecks olanzapine and quetiapine in any cognition paradigm is largely absent. Minimal muscarinic means no acetylcholine bleed-through in cholinergic-adjacent readouts. The 5-HT1A partial agonism adds complexity but also mirrors the profile of vilazodone, making cross-comparison useful in bipolar depression studies. The food-dependent absorption (roughly 350 kcal required) is an annoyance worth noting in preclinical translational design, and akathisia is the dose-limiting signal in clinical contexts.

Where it loses ground is novelty and bench ceiling. The compound is fifteen years old. The clinical literature for schizophrenia and bipolar I depression is well-replicated — multiple phase 3 trials, FDA approval, substantial real-world data — but that evidence base answers clinical questions, not mechanistic ones. If you want a clean 5-HT7 probe with no D2 confound, SB-269970 or SB-656104 are more selective research tools. Lurasidone’s value is translational: it’s what you reach for when you want to connect receptor-level findings back to a clinically-validated pharmacological context.

Thats the honest case for it. Not a frontier compound, not a workhorse for basic receptor characterization, but a well-validated clinical reference tool with the most potent 5-HT7 profile of anything approved. For investigators running bipolar depression models, circadian disruption paradigms, or cognitive-outcome studies where 5-HT7 contribution is the specific variable, it’s genuinely useful and not easily replaced by something better positioned.

Novelty: 33
Mechanism promise: 60
In-category differentiation: 63
Evidence quality: 78
Translational signal: 72
Research bench value: 52

Rationale Lurasidone holds its place as the most potent 5-HT7 antagonist in clinical use, with a selective receptor shape that limits sedation and metabolic confounds useful for cognition and mood paradigms; its 2010 approval and fully characterized mechanism keep novelty and differentiation modest, and the overall score reflects real but bounded bench utility as a translational tool rather than a frontier research target.

Atypical antipsychotic with 5-HT7 antagonism

A benzisothiazole atypical antipsychotic with prominent 5-HT7 receptor antagonism contributing to procognitive and antidepressant effects.

Abstract

Lurasidone ((3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]-cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione; CAS 367514-87-2; molecular formula C28H36N4O2S; molecular weight 492.68) is a benzisothiazole atypical antipsychotic developed at Sumitomo Dainippon and approved by the FDA in 2010 under the trade name Latuda. The receptor profile features full D2 antagonism (Ki approximately 1 nM), potent 5-HT2A antagonism (Ki approximately 0.5 nM), 5-HT1A partial agonism (Ki approximately 6.4 nM), and prominent 5-HT7 antagonism (Ki approximately 0.5 nM, the most potent in clinical use). The 5-HT7 antagonism is associated with procognitive effects and improvement in bipolar depression. H1 and muscarinic activity is minimal, producing low sedation and metabolic burden compared to olanzapine and quetiapine; the principal limitation is dose-related akathisia. Plasma half-life is 18 hours; absorption requires food (approximately 350 kcal). Metabolism is via CYP3A4. Approved for schizophrenia (acute and maintenance), bipolar I depression (monotherapy or with lithium/valproate). Used as the reference 5-HT7-prominent antipsychotic.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-238Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.